This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Sanyal, A. J. et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat. Med. https://doi.org/10.1038/s41591-024-03018-2 (2024)
Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl J. Med. https://doi.org/10.1056/NEJMoa2401943 (2024)
Sanyal, A. J. et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl J. Med. https://doi.org/10.1056/NEJMoa2401755 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Starling, S. A trio of trials on hormone receptor agonists for MASLD. Nat Rev Endocrinol 20, 445 (2024). https://doi.org/10.1038/s41574-024-01015-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-024-01015-6